The Kable

The Kable

Share this post

The Kable
The Kable
💊 Is BA.2 worse? Some say yes. Others say no; Moderna enters the RSV queue; the US FDA gets busy
Copy link
Facebook
Email
Notes
More

💊 Is BA.2 worse? Some say yes. Others say no; Moderna enters the RSV queue; the US FDA gets busy

Vinod's avatar
Vinod
Feb 23, 2022
∙ Paid

Share this post

The Kable
The Kable
💊 Is BA.2 worse? Some say yes. Others say no; Moderna enters the RSV queue; the US FDA gets busy
Copy link
Facebook
Email
Notes
More
Share

In today’s Kable: Homology goes where BioMarin did; Moderna goes where many others did; BioNTech gets into oncology; Lilly goes big on gene therapies; GSK unveils Haleon; Iran returns vaccine doses; Evidence mounting that BA.2 is bad. Or not. 

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Kable
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More